JAK kinase inhibitors

Drug Discovery Today

Volumn 9, Issue 16, 2004, Pages 694-695

  Burns, Christopher ^a   Wilks, Andrew ^a   Su, Stephen ^a  

^a Cytopia Ltd   (Australia)

Author keywords

Biochemistry; Drug Discovery; JAK STAT; signalling; target; therapeutic

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; WHIP 154;

DATA ANALYSIS; DISEASE COURSE; DRUG DESIGN; DRUG TARGETING; GENE IDENTIFICATION; HUMAN; MOLECULAR DYNAMICS; NOTE; SIGNAL TRANSDUCTION; STANDARDIZATION;

ANIMALS; BIOMEDICAL RESEARCH; DRUG DESIGN; HUMANS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 4043112706     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03135-6     Document Type: Note

References (4)

1. Luo C., Laaja P. Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov. Today. 9:2004;268-275
2. Changelian P.S., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 302:2003;875-878
3. Thompson J.E., et al. Photochemical preparation of a pyridone containing tetracycle: a jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12:2002;1219-1223
4. Sachsenmaier C., Schächtele C. Integrated technology platform protein kinases for drug development in oncology. BioTechniques. 33:2002;S101-S106